Alnylam Pharmaceuticals Inc
$ 282.85
-2.26%
12 Jun - close price
- Market Cap 37,764,035,000 USD
- Current Price $ 282.85
- High / Low $ 291.28 / 281.76
- Stock P/E 70.89
- Book Value 8.06
- EPS 3.99
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.90 %
- 52 Week High 495.55
- 52 Week Low 281.77
About
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$438.52
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | 1.99 | 1.25 | 2.9 | 0.32 | -0.01 | 0.06 | -0.5 | 0.56 | -0.16 | -0.77 | 1.74 | -1.62 |
| Estimated EPS | 1.47 | 1.5 | 1.75 | 0.15 | -0.37 | -0.14 | -0.39 | -0.69 | -0.63 | -0.77 | -0.96 | -1.34 |
| Surprise | 0.52 | -0.25 | 1.15 | 0.17 | 0.36 | 0.2 | -0.11 | 1.25 | 0.47 | 0 | 2.7 | -0.28 |
| Surprise Percentage | 35.3741% | -16.6667% | 65.7143% | 113.3333% | 97.2973% | 142.8571% | -28.2051% | 181.1594% | 74.6032% | 0% | 281.25% | -20.8955% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALNY
2026-06-13 00:39:31
Alnylam Pharmaceuticals (ALNY) stock has dropped to a 52-week low of $282.71, reflecting a 27% year-to-date decline and a challenging year for the company. Despite this, the company remains profitable with diluted earnings of $3.95 per share. Recent developments include a 121% increase in Q1 2026 net product revenue, a strategic AI drug discovery collaboration with Inceptive Nucleics, and an expanded commercial partnership with GENESIS Pharma in Nordic markets.
2026-06-12 13:09:55
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its tenth "RNAi Roundtable" webcast series, featuring presentations from Alnylam scientists and medical thought leaders on pipeline programs and unmet clinical needs. The series, which includes webcasts on ALN-6400, Zilebesiran, and ALN-HTT02, reaffirms Alnylam's commitment to advancing RNAi therapeutics and achieving its Alnylam 2030 goals of expanding its clinical pipeline and leveraging AI. The company aims to develop transformative medicines for serious diseases.
2026-06-12 08:09:11
Andra AP fonden significantly increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 134.5% during the fourth quarter, now holding 48,540 shares valued at $19.30 million. This move is part of a broader trend of institutional investment, with other major hedge funds also adjusting their positions in the biopharmaceutical company. Analysts currently rate ALNY as a "Moderate Buy" with a consensus target price of $463.13.
2026-06-11 12:10:40
Alnylam Pharmaceuticals (ALNY) is back in focus due to its 2030 financial goals, the central role of AMVUTTRA, and a new AI partnership. Despite a year-to-date share price drop of 25.6%, the company's long-term returns remain strong, suggesting a potential mispricing as its valuation shows it as undervalued by analysts. However, its high P/E ratio compared to the industry indicates significant optimism already factored into the price.
2026-06-11 09:39:57
Motley Fool Asset Management LLC increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 38.5% in the fourth quarter, acquiring an additional 3,480 shares to a total of 12,526 shares valued at $4.98 million. Institutional investors collectively own 92.97% of the company's stock, with several major firms also adjusting their positions. Alnylam Pharmaceuticals reported strong quarterly results, with EPS of $1.99 against an $0.87 estimate and revenue of $1.17 billion, a 96.4% year-over-year increase.
2026-06-11 06:39:32
GENESIS Pharma and Alnylam Pharmaceuticals have expanded their commercial partnership to include Denmark, Finland, Norway, and Sweden, in addition to thirteen existing Southeast European markets. This collaboration aims to commercialize RNAi therapeutics for serious cardiomyopathy and rare genetic diseases. Both companies emphasize their commitment to increasing patient access to innovative therapies across Europe.
